XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Note 6 - Equity-Based Compensation - Summary of Outstanding RSUs (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) 131,882   131,880
Granted, fair value (in dollars per share)     $ 1.66
Restricted Stock Units (RSUs) [Member]      
Outstanding (in shares)   3,000  
Outstanding, weighted average exercise price (in dollars per share)   $ 15.35  
Outstanding, weighted average remaining contractual term (Year)   4 months 24 days 2 months 12 days
Outstanding, intrinsic value $ 0 $ 0 $ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)   17,627  
Granted, fair value (in dollars per share)   $ 1.66  
Vested and issued, shares underlying restricted stock units (in shares)   (5,937)  
Vested and issued, fair value (in dollars per share)   $ 8.58  
Legacy BioPharmX options, shares underlying options and warrants (in shares) 14,690 14,690 3,000
Outstanding, weighted average exercise price (in dollars per share) $ 1.66 $ 1.66 $ 15.35